EMCURE PHARMACEUTICALS
|
The Current P/E Ratio of EMCURE PHARMACEUTICALS is 33.42.
| Share Price | ₹1,356.7 | Oct 24,2025 |
| Market Cap | ₹25,722.1 Cr | |
| Earnings-TTM | ₹769.7 Cr | TTM-Consolidated Results |
| Price/Earnings | 33.42x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of EMCURE PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹25,722.1 Cr] as on Oct 24,2025
(/) Earnings [ ₹769.7 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 33.42x ]
Thus, for EMCURE PHARMACEUTICALS , the investors are currently willing to pay 33.42 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of EMCURE PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of EMCURE PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of EMCURE PHARMACEUTICALS
PE Ratio Performance Analysis for EMCURE PHARMACEUTICALS
- EMCURE PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 5.97x.
- EMCURE PHARMACEUTICALS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, EMCURE PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 29.84x.
- EMCURE PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does EMCURE PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| EMCURE PHARMACEUTICALS | 769.67 | 33.42 | 25,722.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 39.17 | 407,791.0 |
| DIVIS LABORATORIES LTD | 2,306.00 | 75.84 | 174,885.0 |
| CIPLA LTD | 5,406.81 | 23.66 | 127,930.0 |
| TORRENT PHARMACEUTICALS LTD | 2,002.00 | 60.49 | 121,108.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.73 | 107,164.0 |
| MANKIND PHARMA LTD | 1,905.51 | 52.67 | 100,368.0 |
| ZYDUS LIFESCIENCES LTD | 4,637.80 | 21.82 | 101,192.0 |
| LUPIN LTD | 3,722.18 | 23.70 | 88,221.0 |
| AUROBINDO PHARMA LTD | 3,417.93 | 18.44 | 63,025.7 |
| ABBOTT INDIA LTD | 1,452.29 | 43.81 | 63,628.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs EMCURE PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.44x |
| Max industry PE | 75.84x |
| Median industry PE | 33.42x |
| Average industry PE | 37.43x |
You may also like the below Video Courses